Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2022-02-11 Major Shareholding Noti…
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
AMENDMENT NO. 3 TO SCHEDULE 13G
Major Shareholding Notification
2022-02-11 English
Major Shareholding Notification 2022
Major Shareholding Notification
2022-02-11 English
AMENDMENT NO. 1
Major Shareholding Notification
2022-02-11 English
S-8
Regulatory Filings Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans. It includes details about the securities to be registered, the plans under which they are issued, and references to prior registration statements. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. The document is lengthy (15,000 characters) and contains detailed legal and regulatory information typical of a registration statement. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2022-01-13 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Mereo Biopharma Group PLC, with the SEC. Form 6-K is used by foreign private issuers to report material information that is not required to be filed on Form 20-F. The document includes a press release about clinical trial results but does not contain comprehensive financial statements or detailed financial analysis. The document length is short (1547 characters), and it primarily serves as a regulatory announcement of material information rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-12-22 English
SC 13G
Major Shareholding Notification
2021-12-02 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.